COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022

On September 1, 2022, CDC recommended an updated (bivalent) COVID-19 vaccine booster to help restore waning protection conferred by previous vaccination and broaden protection against emerging variants for persons aged ≥12 years (subsequently extended to persons aged ≥6 months).* To assess the impac...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:MMWR. Morbidity and mortality weekly report Ročník 72; číslo 6; s. 145 - 152
Hlavní autoři: Johnson, Amelia G., Linde, Lauren, Ali, Akilah R., DeSantis, Allison, Shi, Minchan, Adam, Carolyn, Armstrong, Brandy, Armstrong, Brett, Asbell, Madison, Auche, Steven, Bayoumi, Nagla S., Bingay, Boudu, Chasse, Melisse, Christofferson, Scott, Cima, Michael, Cueto, Kevin, Cunningham, Spencer, Delgadillo, Janelle, Dorabawila, Vajeera, Drenzek, Cherie, Dupervil, Brandi, Durant, Tonji, Fleischauer, Aaron, Hamilton, Ross, Harrington, Pauline, Hicks, Liam, Hodis, Jeffrey D., Hoefer, Dina, Horrocks, Sam, Hoskins, Mikhail, Husain, Sofia, Ingram, L. Amanda, Jara, Amanda, Jones, Amanda, Kanishka, F. N. U., Kaur, Ramandeep, Khan, Saadiah I., Kirkendall, Samantha, Lauro, Priscilla, Lyons, Shelby, Mansfield, Joshua, Markelz, Amanda, Masarik, John, McCormick, Donald, Mendoza, Erica, Morris, Keeley J., Omoike, Enaholo, Patel, Komal, Pike, Melissa A., Pilishvili, Tamara, Praetorius, Kevin, Reed, Isaiah G., Severson, Rachel L., Sigalo, Nekabari, Stanislawski, Emma, Stich, Sarah, Tilakaratne, Buddhi P., Turner, Kathryn A., Wiedeman, Caleb, Zaldivar, Allison, Silk, Benjamin J., Scobie, Heather M.
Médium: Journal Article Newsletter
Jazyk:angličtina
Vydáno: United States U.S. Government Printing Office 10.02.2023
U.S. Center for Disease Control
Centers for Disease Control and Prevention
Témata:
Adults
Age groups
Aged
Coronaviruses
COVID-19
COVID-19 - epidemiology
COVID-19 - prevention & control
COVID-19 Vaccines
Death
Death & dying
Dosage
Full Report
Health aspects
Humans
Immunity
Immunization
Incidence
Infections
Jurisdiction
Mortality
Older people
Protection
Public health
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Vaccination
Vaccine efficacy
Vaccines
Viral diseases
United States > US
ISSN:0149-2195, 1545-861X, 1545-861X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:On September 1, 2022, CDC recommended an updated (bivalent) COVID-19 vaccine booster to help restore waning protection conferred by previous vaccination and broaden protection against emerging variants for persons aged ≥12 years (subsequently extended to persons aged ≥6 months).* To assess the impact of original (monovalent) COVID-19 vaccines and bivalent boosters, case and mortality rate ratios (RRs) were estimated comparing unvaccinated and vaccinated persons aged ≥12 years by overall receipt of and by time since booster vaccination (monovalent or bivalent) during Delta variant and Omicron sublineage (BA.1, BA.2, early BA.4/BA.5, and late BA.4/BA.5) predominance. During the late BA.4/BA.5 period, unvaccinated persons had higher COVID-19 mortality and infection rates than persons receiving bivalent doses (mortality RR = 14.1 and infection RR = 2.8) and to a lesser extent persons vaccinated with only monovalent doses (mortality RR = 5.4 and infection RR = 2.5). Among older adults, mortality rates among unvaccinated persons were significantly higher than among those who had received a bivalent booster (65-79 years; RR = 23.7 and ≥80 years; 10.3) or a monovalent booster (65-79 years; 8.3 and ≥80 years; 4.2). In a second analysis stratified by time since booster vaccination, there was a progressive decline from the Delta period (RR = 50.7) to the early BA.4/BA.5 period (7.4) in relative COVID-19 mortality rates among unvaccinated persons compared with persons receiving who had received a monovalent booster within 2 weeks-2 months. During the early BA.4/BA.5 period, declines in relative mortality rates were observed at 6-8 (RR = 4.6), 9-11 (4.5), and ≥12 (2.5) months after receiving a monovalent booster. In contrast, bivalent boosters received during the preceding 2 weeks-2 months improved protection against death (RR = 15.2) during the late BA.4/BA.5 period. In both analyses, when compared with unvaccinated persons, persons who had received bivalent boosters were provided additional protection against death over monovalent doses or monovalent boosters. Restored protection was highest in older adults. All persons should stay up to date with COVID-19 vaccination, including receipt of a bivalent booster by eligible persons, to reduce the risk for severe COVID-19.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0149-2195
1545-861X
1545-861X
DOI:10.15585/mmwr.mm7206a3